IMRX
Immuneering Corporation
Healthcare · Biotechnology · NGM
$4.27
Data: 2026-05-14
✗ ETHICAL FAIL

MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$348M
Total market value of the company
Trailing P/E
0.00
Forward P/E
-3.98
Based on estimated future earnings — lower means cheaper
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
ROE
-43.1%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$17.00
+298% from current price — median analyst estimate
Recommendation
NONE
Consensus view from 6 analysts covering this stock
About Immuneering Corporation

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

https://immuneering.com

Country: United States Employees: 53 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
1.1% PASS
Debt must be below 33% of total assets
Cash Ratio
49.7% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKDOWN
Price trending down — defensive positioning
Sharpe Ratio
1.120
Excellent risk-adjusted returns
Kelly Fraction
0.0631
Suggested allocation is meaningful — the edge justifies a position
Calmar Ratio
1.404
Returns exceed worst-case losses — strong risk profile
Annual Return
92.3%
Historical annualised return based on price data
Max Drawdown
-65.7%
Largest peak-to-trough decline — the worst it has been
HMM State
CRISIS
Elevated risk detected — extreme caution warranted
Days in State
74
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.36
Very low correlation to market moves
52W High
$10.08
58% below the year high
52W Low
$1.29
231% above the year low
Avg Volume
862,074
Average daily shares traded — higher means easier to buy and sell
Short Ratio
12.4
Days it would take all short sellers to cover — higher means more crowded
Short % Float
19.4%
Elevated short interest — bears are positioned against this
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-1.27
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.02
Conservative use of debt — low financial risk
Current Ratio
17.50
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
17.16
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Free Cash Flow
$-28,047,836
Negative — the business is spending more than it generates
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
$-56,024,896
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
6
Target High
$30.00
Target Median
$17.00
Target Low
$11.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-03-13 NEUFELD LEAH R Officer 3,628 $15,573
2026-01-16 BRAKEWOOD HAROLD EUGENE Officer 5,250 $24,990
2026-01-15 SCHALL THOMAS J Director 21,645 $101,041
2026-01-15 HALL BRETT MATTHEW Officer 2,298 $10,502
2026-01-13 NEUFELD LEAH R Officer 2,626 $10,906
2026-01-12 FEINBERG PETER Director 20,000 $86,904
2025-10-03 FEINBERG PETER Director 7,500 $50,025
2025-10-01 BOOKMAN MICHAEL Officer 1,020 $6,966
2025-10-01 MORALES MALLORY Officer 300 $1,917
2025-10-01 NEUFELD LEAH R Officer 800 $5,103
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.